Market capitalization | $259.87m |
Enterprise Value | $234.36m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 56.47 |
P/S ratio (TTM) P/S ratio | 62.62 |
P/B ratio (TTM) P/B ratio | 34.08 |
Revenue growth (TTM) Revenue growth | -73.62% |
Revenue (TTM) Revenue | $4.15m |
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
5 Analysts have issued a DBV Technologies SA Sponsored ADR forecast:
5 Analysts have issued a DBV Technologies SA Sponsored ADR forecast:
Dec '24 |
+/-
%
|
||
Revenue | 4.15 4.15 |
74%
74%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -112 -112 |
29%
29%
|
EBIT (Operating Income) EBIT | -116 -116 |
53%
53%
|
Net Profit | -114 -114 |
57%
57%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Head office | France |
CEO | Daniel Tassé |
Employees | 110 |
Founded | 2002 |
Website | www.dbv-technologies.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.